Epizyme Profit Margin

The latest profit margin for EPZM is -403.17% as of June 2022. That compares with -788.6% in the prior-year period — up 48.9% year over year. That is below the Healthcare sector average of 19.13%. Investors often review this figure alongside Epizyme's historical trend and sector peers before judging valuation or financial health.

Over the past year, EPZM's profit margin moved from -788.6% to -403.17% — a 48.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Epizyme's valuation or profitability profile.

Against Healthcare companies, EPZM currently prints -403.17% for profit margin, while the sector average sits near 19.13%. That is roughly 2207.4% below the sector mean. Large gaps often invite a closer look at Epizyme's growth, margins, and balance sheet.

Profit Margin shows how effectively Epizyme converts resources into returns. At -403.17%, EPZM may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -788.6% in the prior-year period — up 48.9% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting EPZM's profit margin (-403.17%), review year-over-year change from -788.6%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.